Canada markets closed

DBV Technologies S.A. (DBV.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.27000.0000 (0.00%)
At close: 09:16AM CET
Full screen
Previous Close1.2700
Open1.2580
Bid1.2570 x 6000
Ask1.4080 x 6000
Day's Range1.2580 - 1.2700
52 Week Range1.2540 - 4.1600
Volume317
Avg. Volume0
Market Cap128.054M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.7000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Insider Monkey

    DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript

    DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript March 7, 2024 DBV Technologies S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results […]

  • GlobeNewswire

    DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

    Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K wi

  • GlobeNewswire

    DBV Technologies Reports Full Year 2023 Financial Results and Business Update

    Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Strengthened executive leadership team in preparation for BLA submissionReported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa